Enhancement Vehicles of Cardene Loading Poly(D,L-lactic-co-glycolic acid) Nanoparticles in Vitro Controlled Release for Biomedical Application

Nopparuj Soomherun1, Narumol Kreua-ongarjnukool1, Saowapa Thumsing Niyomthai1, and Sorayouth Chumnanvej2

1Department of Industrial Chemistry, Faculty of Applied Science, King Mongkut’s University of Technology North Bangkok, Bangkok, Thailand
2Neurosurgery Unit, Surgery Department, Faculty of Medicine Ramathibodi Hospital Mahidol University, Bangkok, Thailand
Email: n.soomherun@gmail.com, {narumol.k, saowapa.t}@sci.kmutnb.ac.th, sorayouth.chu@mahidol.edu

Abstract—The goal of this research was to prepare a nanovehicles from Poly(D,L-Lactic-co-Glycolic Acid) Nanoparticles (PLGA NPs) for delivering cardene. The cardene loading-PLGA NPs were fabricated by double emulsion and solvent evaporation process. PLGA has a monstrous interest to fabricate nanoparticles due to its good biodegradability and excellent biocompatibility. Drug loading and release profiles were performed as the model drug. The results appeared that cardene amount from 5.0 mg to 30.0 mg lead to the increase of the particle size, Polydispersity Index (PDI), and nanoparticle yield. The drug encapsulation efficiency was approximately 77% to 92%. The in vitro release from PLGA NPs was prolonged cardene concentration at periods more than 16 to 41 days. The cumulative drug release was a maximum of 40% to 70%. Moreover, the nanoparticles could be demonstrated biocompatible with the keratinocyte cells by MTT assay. The cardene loading-PLGA NPs were able to protect drug degradation and improve pharmacokinetics during transporting to the targeted organ. The cardene loading-PLGA NPs could be applied to prolonged drug delivery in biomedical applications.

Index Terms—poly(D,L-lactic-co-glycolic acid), cardene, nanoparticles, controlled release

I. INTRODUCTION

Nanotechnology in vehicles for biomaterial application has been nanoparticles for drug delivery to the protection of drug degradation and improved pharmacokinetics during transportation to targeted organs [1], as depicted in Fig. 1. Therefore, the researcher decided to study about the enhancement vehicles of cardene loading-Poly(D,L-Lactic-co-Glycolic Acid) Nanoparticles (PLGA NPs) in vitro controlled release for biomedical application.

PLGA NPs based controlled drug delivery are appropriated administration of drugs into the body in many ways. It is protected drugs to safely deactivation and maintained therapeutic drug concentrations. Including, PLGA NPs are improved pharmacokinetics during transport to the target organ for reducing the side effects of the drug [1], [2]. Cardene was a model drug in this work to study drug load and in vitro controlled release. Cardene is an antihypertensive drug class. It has been used clinically to treat high blood pressure and relaxes blood vessels leads to reduce pumping of the heart [3]. Fig. 1 shows examples of a conventional cardene for terminal hypertension, conventional dosage forms are degradable of the drug in 8 hrs. The half-life of cardene is short-acting which is insufficient for therapeutic levels. The ester linkage in the structure of cardene was degraded by hydrolysis reaction. [4], [5]. The drug concentrations are below than therapeutic concentrations, the patient has high blood pressure. Drug dose maintenance to therapeutic action is achieved by repeated administrations for relieving hypertension. Repeated administrations may result in a drug overdose, which the patient gets dangerous side effects like slower heart rate and dizziness [6].

With the above motivation, the hypothesis of this research was the case that cardene loading-PLGA NPs could be the protection of cardene deactivation, control drug level in the body, and reduce side effects. The development of cardene pharmacokinetics is a classic problem in the pharmaceutical. A popular use of biopolymers that are enhanced to expand drug lives is established by pharmaceutical carriers [7]. There has shown significant potential as protection of drugs from deactivation and preservation of its activity during transport to the target organ. Among all the biomaterial indicated enormous potential as drug delivery [8]-[12] and as tissue engineering [13]-[15]. This study used PLGA nanoparticles as a drug delivery system because PLGA is polyester that a block copolymer of Poly(D,L-Lactic Acid) (PDLLA) and Polyglycolic Acid (PGA) [8]. This biopolymer was degraded by esterase enzyme and hydrolysis in the body with non-toxic by-products [16].
The purpose was to prepare vehicles of PLGA NPs for prolonging the cardene delivery system.

**Figure 1.** Drug concentrations at the site of therapeutic action as a conventional vasodilator drug (dash line) and PLGA NPs as a controlled released drug (solid line) [1].

## II. METHOD

### A. Preparation of the Cardene Loading-PLGA NPs

1) **Materials**

Poly(D,L-Lactic-co-Glycolic Acid) (PLGA: Mw 24,000-38,000 Da and 50:50 ratio of PDLLA: PGA) and poly(vinyl alcohol) (PVA; Mw. ∼31,000 Da) were purchased from Sigma-Aldrich (USA). Keratinocyte cells line, Dulbecco’s Modified Eagle’s Medium (DMEM), and MTT reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) were purchased from Sigma-Aldrich (USA). Cardene was obtained from Ramathibodi Hospital, Bangkok, Thailand. Dichloromethane and acetone were of analytical grade.

2) **Method**

The cardene loading-PLGA NPs were fabricated by double emulsion process. This research was studied various cardene amounts from 5.0 mg to 30.0 mg. 4.0 %w/v of PLGA concentration was dissolved in mixed solution acetone with dichloromethane 2.0 mL. The 1.0 mL aqueous solution of cardene and 3.0 %w/v single emulsion stabilizer was subsequently mixed to this polymer solution. Next, this solution was again ultrasonicated (Model VCX 500, USA), under ice-cooling, forming a single emulsion. The single emulsion was added and ultrasonicated in 0.5 %w/v of PVA 30 mL as a secondary stabilizer for a double emulsion. The solvent evaporation of the double emulsion was stirred with a magnetic stirrer at 30 °C and 3 hrs. Finally, the cardene loading-PLGA NPs were collected by centrifugation (UNIVERSAL 320, Germany) and washed three times with DI water. The obtained cardene loading-PLGA NPs were drying by freeze-drying (Pirani 501, USA) and were stored at 4 °C for analysis nanoparticle characterization, encapsulation efficiency (%EE), and *in vitro* drug release. All of this results in this research were analyzed by a statistical package in terms of means and S.D.

### B. Size and Surface Morphology Analysis

The cardene loading-PLGA NPs were analyzed particle size and polydispersity index (PDI) by dynamic light scattering (DLS; Malvern Zetasizer Nano ZSP, UK).

The cardene loading-PLGA NPs were to analyze the surface morphology of the produced nanoparticles with field emission scanning electron microscope (FE-SEM; JEOL JSM-7610F, Japan).

### C. Nanoparticle Yield

The cardene loading-PLGA NPs were collected and weighed accurately. The percentage of yield (%Yield) can be described as (1) [17]:

\[
\text{Yield} = \frac{\text{Mass of nanoparticles}}{\text{Total mass of PLGA and Drug}} \times 100
\]

### D. Nanoparticle Settling Velocity

The cardene loading-PLGA NPs were studied settling velocity (v) of nanoparticle suspended in a liquid by Stokes’ law as (2) compare that of Brownian motion was calculated as (3) [18].

\[
v = \frac{d^2 g (\rho_s - \rho_l)}{18 \mu_l} \quad (2)
\]
\[
\chi = \sqrt{\frac{2k_B T \pi \mu \eta d}{m}} \quad (3)
\]

where \(v\) is the nanoparticle settling velocity by Stokes’ law (nm/sec), \(\chi\) is the average Brownian displacement (nm/sec), \(g\) is the gravitation acceleration (9.8 m/sec), \(\rho_s\) is the nanoparticle density (1.3 g/cm³), \(\rho_l\) and \(\mu\) is the Di water density (1.0 g/cm³) and viscosity (8.9 \times 10^{-4} Pa/sec) at room temperature, respectively, \(k_B\) is the Boltzmann constant (1.38 \times 10^{-23} J/K), \(T\) is the room temperature (K), \(t\) is the time (1 sec), and \(d\) is the diameter of nanoparticles.

### E. Nanoparticle Bulk Settling

The study of nanoparticles settling times in liquids. 50.0 mg of produced nanoparticles were dispersed in 10.0 mL of DI water. The colloidal stability of cardene loading-PLGA NPs dispersion was investigated variation in the measurements of average diameter and time with laser scattering techniques (DLS; Malvern Zetasizer Nano ZSP, UK).

### F. Encapsulation Efficiency

The cardene loading-PLGA NPs were investigated the %EE by UV-Visible spectrophotometer (SPECORD 210 PLUS, Germany) at a wavelength of 359 nm, can be represented by the (4) [19]:

\[
\text{%EE} = 100 - \frac{B}{A} \times 100 - C \quad (4)
\]

where \(A\) is the total amount of cardene, \(B\) is the unencapsulated cardene in PLGA NPs, and \(C\) was the cardene adsorbed in aqueous solution.
G. In Vitro Drug Release

The cardene loading-PLGA NPs were determined 100 mg of nanoparticle suspended in a pH 7.4 of Phosphate-Buffered Solution (PBS) to mimic the body fluids in normal tissues. This solution was incubated at 37 °C and 70 rpm in the shaking water bath (GFL 1086, Germany). The supernatant release medium was pipetted 3.0 mL and added 3.0 mL new PBS back to the solution at a preset time following incubation. This pipette solution was investigated in vitro drug release by UV-Visible spectrophotometer at a wavelength of 359 nm, as calculated by (5) [20]:

$$\text{Cumulative release(%) = } \left( \frac{M_i}{M_\infty} \right) \times 100$$ (5)  

where $M_i$ is the cardene amount released from the PLGA NPs at time t and $M_\infty$ is the total amount of cardene loading-PLGA NPs.

H. In Vitro Cytotoxicity Assay

Cell cytotoxicity was investigated by MTT assay. This protocol is a colorimetric reaction that leads to a transform of color based on metabolically active cells. The yellow tetrazolium salt is converted to purple formazan by the potentiality of viable cells. Keratinocyte cells were determined to study cytotoxicity of the cardene loading-PLGA NPs.

The 125 µg/mL of nanoparticles were sterilized by 6 watts UV radiation (Analytik Jena, Germany) on 254 nm wavelength band centered for 120 min and incubated in free bioactive compounds. During incubation, these cells were seeded at 1.0 x10^4 cell/well in 96-well culture plates containing DMEM with bioactive compounds. This incubation was added 0.5 mg/mL of MTT reagent at 37 °C in 5% CO\textsubscript{2} incubator. The colorimetric reaction of cell viability was investigated using UV-visible spectrophotometer at a wavelength of 570 nm [7].

III. RESULTS AND DISCUSSION

A. Preparation of the Cardene Loading-PLGA NPs

The research results appeared that the nanovehicles of cardene loading-PLGA NPs using in vitro controlled release was prepared by a double emulsion and solvent evaporation process. The cardene amounts may be a key factor influencing the nanoparticle characterization like particle size, surface morphology, nanoparticle yield, and nanoparticle settling velocity, %EE, and in vitro drug release.

B. Size and Surface Morphology Analysis

In the first study, the effect of cardene amounts that influenced the size of nanoparticles was investigated. The results indicated that 5.0 mg, 10.0 mg, 20.0 mg, and 30.0 mg of cardene amount in this work were prepared to obtain less average particle size 200 nm by DLS technique, as illustrated in Fig. 2. The amount of 5.0 mg to 20.0 mg cardene had appeared a narrower size distribution with a particle size of ~170 nm to ~176 nm. In the case of 30.0 mg of the cardene amounts was prepared an average particle size of ~184 nm and abroad size distribution with nanoparticle sizes ranging from ~30 nm to ~650 nm due to the charge are driven against the rising electrostatic potential between polymeric and drug [4], [5], [8]. In addition, the high amounts of cardene in the solution was increased the hydrophilic substance amounts in aqueous solution. It is a weak interaction of polymer layer and drug layer; which polymer chains can easily move in a polymeric matrix led to the increased size of produced nanoparticles. As a result, the increase of cardene amounts from 5.0 mg to 30.0 mg was increased size and a broad range of size distributions.

![Figure 2. Particle sizes (a) and size distributions (b) of the cardene loading-PLGA NPs (n = 3); (a, b are significantly different at P≤ 0.05; compared with the nanoparticles in each group).](image-url)

Fig. 3. shows SEM micrographs of different the cardene amounts. The cardene loading-PLGA NPs were still the same size and size distributions according to DLS technique. The SEM images were observed a few produced nanoparticles with diameters higher than 500 nm. The obtained result of PDI values, the produced nanoparticles in this research had size distributions of 100 to 600 nm in diameter, as shown in Fig. 2 (b). The surface morphology of nanoparticles was spherical with smooth surfaces. However, the SEM micrographs observed capillary bridging between nanoparticles. The capillary bridging was probably resulting from an incomplete PVA washing process before collecting nanoparticles. Nevertheless, all cases of nanoparticles in this research were produced it have homologous properties in each group since PDI values were less than 0.3 indicates monodispersity [21]. It is presented systematically in Table I.
C. Nanoparticle Yield

The yield is the percentage successfully produced nanoparticles in this work. Table I describes the yield of nanoparticles produced by the various amount of cardene was ~ 64% by calculated as follows (1) [17]. It can be extrapolated that, as the amounts of cardene increases, was the effect on a low influence of nanoparticle yield.

| Cardene-loading (mg) | PDI values | Yield (%) |
|----------------------|------------|-----------|
| 5.0                  | 0.152±0.032 | 64.98±1.75a |
| 10.0                 | 0.185±0.027 | 63.48±1.55b |
| 20.0                 | 0.232±0.042  | 65.11±0.92b |
| 30.0                 | 0.257±0.053  | 66.33±1.04b |

Remark: a, b are significantly different at P≤ 0.05; compared with the nanoparticles in each group.

D. Nanoparticle Settling Velocity

The cardene loading-PLGA NPs have studied the action or process of precipitating via Stokes’ law and Brownian motion equation. Stokes’ law, the nanoparticles were transferred down to bottom, which leads to precipitating under gravitational force. Conversely, the common of nanoparticles move randomly in a fluid according to Brownian motion. The random movement of nanoparticles can be suspended when immersed in a liquid environment. The calculation on Stokes’ law is less than the calculation on the Brownian motion equation, lead to nanoparticles produced opposite of precipitation, which was calculated as follows (2) and (3), respectively [18].

The effect of cardene amounts has a direct influence on precipitating because it affects the size of cardene loading-PLGA NPs, as appeared in Fig. 2 (a). The diameter of nanoparticles has an enormous influence on Stokes’ law, as observed (2) [18]. The results appeared that the increase of cardene amounts led to the increase of the nanoparticle diameter, resulting in an increased of precipitating via Stokes’ law. However, all study of Brownian displacement has more calculated value than settling velocity of Stokes’ law. As a result, the nanoparticles produced can spread immersed in a liquid environment, as illustrated in Fig. 4. The small size of particles in this work can easy suspended in a liquid. The large size of particles has a strong force of gravity than nanoparticles. The large microparticles larger can easily precipitate under gravitational force, therefore it needs to a label as “shake well before use” [18].

E. Nanoparticle Bulk Settling

The result of settling velocity indicated that produced nanoparticles were not settling in DI water. In this study, for confirmation of nanoparticles settling times for 24 hrs. by laser scattering techniques and the results are appeared in Fig. 5. The cardene loading-PLGA NPs remained rather stable at room temperature, as demonstrated by the investigating of average diameter were softly increased with approximately 32 nm (<21 %) after 24 hrs.
the monodispersity of stabilizer molecules. The stabilization was achieved steric monodispersity of cellulose molecules as a single stabilizer attached to the inner surface of nanoparticles and PVA molecules as a secondary stabilizer forming a coating on the outer surface of nanoparticles. The steric of stabilizer established a repulsive force that leads to separates the nanoparticles from another one [22].

F. Encapsulation Efficiency

The %EE is the percentage of cardene amounts that are successfully entrapped into the PLGA NPs, which calculated by (4). In order to determine the %EE of nanoparticles was depending on the cardene amount. The results appeared that the increase of the cardene amount led to the decrease of the %EE, as shown in Fig. 6. However, the 30.0 mg of the cardene amounts had a minimum of the %EE (76.81%); conversely, it had high drug entrapment about ~23.04 mg. High amounts of cardene in the solution were driven off the polymeric matrix via the electrostatic potential on the surface. Moreover, the cardene entrapment in nanoparticles was affected by the aqueous phase, which aqueous volume consistent whose drug solubility decreases when the cardene amounts increase.

G. In Vitro Drug Release

In this work enhanced the PLGA NPs as controlled release vehicles of cardene. The produced nanoparticles were incubated at 37°C and 70 rpm of a shaking water bath in pH 7.4 of PBS to mimic the body fluids in normal tissues. Fig. 7 shows the in vitro cardene releases profiles illustrated the controlled release of cardene from nanoparticles in period time from 16 to 41 days. The high amount of cardene was increased the release times. The 5.0 mg of the cardene amounts had a maximum of the %EE (91.93%); conversely, it had the least amount of cardene load in the PLGA NPs influence less release time. However, the 5.0 mg of cardene amount was obtained high cumulative release since the less total amount of cardene loading-PLGA NPs can be calculated as (5) [20]. In this work, the cardene loading-PLGA NPs have indicated the in vitro cardene releases from nanoparticles as prolong drug delivery vehicles.

H. In Vitro Cytotoxicity Assay

From MTT assay, to study the cytotoxicity of 125 mg/mL. cardene loading-PLGA NPs were incubated with keratinocyte cells (normal cells) for 24 h and 37 °C. The addition of cardene amount was expanded absorbance purple formazan of MTT reagent. The increased of purple absorbance was indicated higher relative cell viability after 24 hrs. The result was produced nanoparticles in this work do not demonstrate the toxicity of the keratinocyte cells. The cardene loading-PLGA NPs could be demonstrated biocompatible with the keratinocyte cells, as illustrated in Fig. 8.

IV. CONCLUSION

The study of cardene amount was able to prepare nanovehicles of the cardene loading-PLGA NPs for controlled release systems. The morphological of nanoparticles presented a spherical shape and smooth surfaces which had the particle size from 170 nm to 184 nm. The nanoparticles showed the times of stabilizers after 24 hrs. The percentage of cardene encapsulated within nanoparticles was approximately 77% to 92%. The PLGA nanoparticles prolonged the release of cardene for up to 16 days in vitro. The 5.0 mg to 30.0 mg of cardene amounts...
was non-cytotoxicity for the keratinocyte cells with produced nanoparticles. The results were indicated that the enhancement of cardene loading-PLGA NPs could be controlled release for drug delivery nanovehicles in biomedical applications.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS
N. Soomherun designed and performed the experiments with support from all authors; conducted the research, analyzed the data, and co-wrote the paper; N. Kreuangoarjnikool, S. T. Niyomthai and S. Chummnanvej were involved in planning and supervised the research, processed the experimental data, co-wrote the paper, reviewing, editing, and contributed to the interpretation of the results; all authors had approved the final version and provided critical feedback on the paper.

ACKNOWLEDGMENT
Authors would like to thank Neurosurgery Unit, Surgery Department, Faculty of Medicine Ramathibodi Hospital Mahidol University, Thailand for the supported cardene employed in this study. Special thanks to the partial financial support from (a) Chuan Ratanarak Foundation, (b) Graduate College, and (c) Industrial Chemistry Department, Faculty of Applied Science, King Mongkut’s University of Technology North Bangkok, Thailand are appreciatively acknowledged (in house grant).

REFERENCES
[1] C. T. Huynh and D. S. Lee, “Controlled release,” in Encyclopedia of Polymeric Nanomaterials, New York: Springer-Verlag, 2015, pp. 1-12.
[2] 2019 hypertension. World Health Organization Publishing. [Online]. Available: hhtps://www.who.int/news-room/factsheets/detail/hypertension
[3] J. C. Wanstall and S. R. O. Donnell, “Responses to vasodilators drugs on pulmonary artery preparations from pulmonary hypertensive rats,” Br. J. Pharmacol., vol. 105, pp. 152-158, 1992.
[4] M. P. Curran, D. M. Robinson, and G. M. Keating, “Intravenous nicardipine: Its use in the short-term treatment of hypertension and various other indications,” Drugs, vol. 66, no. 13, pp. 1755-1782, 2006.
[5] S. M. A. Ghannam and A. M. A. Olayan, “Stability-indicating HPLC method for the determination of nicardipine in capsules and spiked human plasma. Identification of degradation products using HPLC/MS,” Arab. J. Chem., vol. 12, no. 8, pp. 1983-1993, 2014.
[6] W. F. Peacock, et al., “CLUE: A randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department,” Crit. Care., vol. 15, no. 3, R157, 2011.
[7] S. Thumsing, N. Iresena, C. Boonkrka, and P. Supaphol, “Preparation of bioactive glycosylated gelatine gel-cell–line derived neurotrophic factor–loaded microspheres for medical applications,” J. Appl. Polym. Sci., vol. 131, no. 8, article 40168, 2013.
[8] H. K. Makadia and S. J. Siegel, “Poly Lactic-Co-Glycolic Acid (PLGA) as biodegradable controlled drug delivery carrier,” Polymers, vol. 3, pp. 1377-1397, 2011.
[9] D. Bhambure, B. Shrivastava, P. Sharma, N. Bukane, and P. Gide, “Preparation and optimization of dry PLGA nanoparticles by spray drying technique,” Particul. Sci. Technol., vol. 31, pp. 533-540, July 2013.
[10] J. Zhao, et al., “Development of near zero-order release PLGA-based microspheres of a novel antipsychotic,” Int. J. Pharm., vol. 516, pp. 32-38, January 2017.
[11] S. Thumsing and P. Supaphol, “Gelatin microspheres containing multi-walled carbon nanotubes: Preparation, characterization, and use as a drug carrier,” Chiang. Mai. J. Sci., vol. 41, pp. 1287-1300, October 2014.
[12] C. N. Limjeerajarus, et al., “Prolonged release of iloprost enhances pulpal blood flow and dentin bridge formation in a rat model of mechanical tooth pulp exposure,” J. Oral. Sci., vol. 61, pp. 73-81, March 2019.
[13] A.R. Rosa, et al., “Development of VEGF-loaded PLGA matrices in association with mesenchymal stem cells for tissue engineering,” Braz. J. Med. Biol. Res., vol. 50, article e5648, August 2017.
[14] X. Liang, et al., “Bilayered PLGA/PLGA-HAp composite scaffold for osteochondral tissue engineering and tissue regeneration,” ACS Biomater. Sci. Eng., vol. 4, pp. 3506-3521, August 2018.
[15] L. Zhou, et al., “Combining PLGA scaffold and MSCs for brain tissue engineering: A potential tool for treatment of brain injury,” Stem. Cells. Int., vol. 2018, article 5024175, August 2018.
[16] P. Gentile, V. Chiono, I. Carmagnola, and P. V. Hatton, “An overview of poly(lactic-co-glycolic) acid (PLGA)-based biomaterials for bone tissue engineering,” Int. J. Mol. Sci., vol. 15 no. 3, pp. 3640-3659, February 2014.
[17] Y. Xu and M. A. Hanna, “Electrospray encapsulation of watersoluble protein with poly lactide: Effects of formulations on morphology, encapsulation efficiency and release profile of particles,” Int. J. Pharm., vol. 320, pp. 30-36, August 2006.
[18] R. B. Gupta, “Fundamentals of drug nanoparticles,” in Nanoparticle Technology for Drug Delivery, R. B. Gupta and U. B. Kompella, Eds., New York: Taylor & Francis, 2006, ch. 1.
[19] N. Soomherun, N. Kreuangoarjnikool, S. Chummnanvej, and S. Thumsing, “Encapsulation of nicardipine hydrochloride and release from biodegradable poly(D.L-lactic-co-glycolic acid) microparticles by double emulsion process: Effect of emulsion stability and different parameters on drug entrapment,” Int. J. Biomater., vol. 2017, article 1743765, November 2017.
[20] X. Shi, Y. Zheng, G. Wang, Q. Lin, and J. Fan, “pH- and electroresponsive characteristics of bacterial cellulose nanofiber sodium alginate hybrid gel for the dual controlled drug delivery,” RSC Adv., vol. 4, pp. 47056-47065, September 2014.
[21] C. Wang, et al., “Fabrication and evaluation of lambdacyhalothrin nanosuspension by one-step melt emulsification technique,” Nanomater., vol. 9, no. 2, article 145, January 2019.
[22] C. D. Armit and R. Rothon, “Dispersants and coupling agents,” in Applied Plastics Engineering Handbook: Processing, Materials, and Applications, M. Kutz, Ed., New York: Elsevier, 2017, ch. 22, pp. 501-516.

Nopparaj Soomherun, PhD. Candidate, was born on April 30, 1991. He is a graduate of the second class honors degree in the Bachelor of Science Degree and Master of Science Degree in Industrial Chemistry from Department of Industrial Chemistry, Faculty of Applied Science, King Mongkut’s University of Technology North Bangkok, Thailand. He received the Best Paper Award 2015 from the 24th International Conference on Engineering and Natural Science, Waseda University, Japan. He has been practicing research assistant to develop an encapsulation at the Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand since 2016. He is interested in nanotechnology, encapsulation, biopolymer, material science, and drug delivery system.

©2021 Int. J. Pharm. Med. Biol. Sci.
Narumol Kreua-ongjarunjukool was born in Bangkok, Thailand, in 1960. She received the second class honors degree in the bachelor degree in chemistry from Srinakharinwirot University and Master of Science degree in Chemistry from the Department of Chemistry, Faculty of Science, Chulalongkorn University. She is an Associate Professor at the Department of Industrial Chemistry, Faculty of Applied Science, King Mongkut's University of Technology North Bangkok (KMUTNB). She is a member and the secretary of the Chemical Society of Thailand under the Patronage of Her Royal Highness Princess Chulabhorn Krom Phra Sri savangkavadhana. She received the outstanding research advisor award in 2017 from graduate school, KMUTNB. She has been joining the research to develop nanocarriers for drug delivery of in intraoperative Cerebrovascular Surgery at the Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand since 2013. Her research interests include the fields of material science, micro/nano-encapsulation for biomedical application, biopolymer for drug delivery system and wound dressings materials. She recently received the most outstanding employee award 2018 from KMUTNB. She has published the research paper in the various journals and in the proceedings of the international conferences.

Saowapa Thumsing Niyomthai was born in Thailand, in 1986. She received the first honors degree in the bachelor science degree in industrial chemistry, Department of Industrial Chemistry, Faculty of Applied Science, King Mongkut’s University of Technology North Bangkok, Thailand, and PhD. degree in Polymer Science from The Petroleum and Petrochemical College, Chulalongkorn University (An international program, in academic partnership with The University of Michigan, The University of Oklahoma, and Case Western Reserve University). In 2016, she joined the Department of Industrial Chemistry, Faculty of Applied Science, KMUTNB, Thailand as a Lecturer. She is a Life Member of the Chemical Society of Thailand. Her research fields are material science, micro/nanoencapsulation for biomedical application, electrostatic spinning of polymer, biopolymer for drug delivery system, wound dressings and cell/tissue scaffolding materials.

Sorayouth Chumnanvej, MD, PhD., was born on Dec 24, 1971. He is a graduate of Thammasat University Medical School. He trained in neurosurgery at Mahidol University since 1999 and Clinical Research Fellow at Brigham and Women & Children Hospital, Harvard Medical School, Boston, MA, USA since 2006. Chumnanvej has been practicing in neurosurgery since 2002. He holds PhD degree in biomedical engineering from Mahidol University. He also specializes and is interested in robotic assisted surgery. He is also the director of the furthering program of organ donor and procurement management at Faculty of Medicine Ramathibodi Hospital, Mahidol University. Dr. Chumnanvej is a clinical assisted professor of neurosurgery at Faculty of Medicine Ramathibodi Hospital, Mahidol University. He is a fellow in the Royal College of Neurological Surgeons of Thailand. He recently received the ICS Inventor Award 2019 from the Royal College of Surgeons of Thailand (RCST).